Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: Current status and future directions

Clinical Cancer Research

Volumn 13, Issue 4, 2007, Pages 1098-1106

  Rini, Brian I ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; BEVACIZUMAB; ERLOTINIB; EVEROLIMUS; INTERFERON; INTERLEUKIN 2; PLACEBO; PLATELET DERIVED GROWTH FACTOR A; PLATELET DERIVED GROWTH FACTOR B; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PLATELET DERIVED GROWTH FACTOR D; PROTEIN TYROSINE KINASE INHIBITOR; RAF PROTEIN; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TRANSFORMING GROWTH FACTOR ALPHA; VASCULOTROPIN;

ANOREXIA; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DIGESTIVE SYSTEM PERFORATION; DRUG BINDING; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG FATALITY; DRUG INHIBITION; DRUG MECHANISM; DRUG MEGADOSE; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; HAND FOOT SYNDROME; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; HYPOPHOSPHATEMIA; KIDNEY CARCINOMA; LEUKOPENIA; LONG TERM CARE; LOW DRUG DOSE; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PATIENT SELECTION; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RASH; REVIEW; SOLID TUMOR; STOMATITIS; T LYMPHOCYTE ACTIVATION; THROMBOEMBOLISM; TREATMENT RESPONSE;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, RENAL CELL; CLINICAL TRIALS; HUMANS; INDOLES; KIDNEY NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN KINASE INHIBITORS; PYRIDINES; PYRROLES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33947288597     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-1989     Document Type: Review

References (64)

1. Coppin C, Porzsolt F, Awa A, Kumpf J, Coldman A, Wilt T. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 2005 Jan 25(1);CD001425.
2. Fyfe GA, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Long-term response data for 255 patients with metastatic renal cell carcinoma treated with high-dose recombinant interleukin-2 therapy. J Clin Oncol 1996;14:2410-1.
3. Ferrara N. Vascular endothelial growth factor as a target for anticancer therapy. The Oncologist 2004;9: 2-10.
4. Rini BI, Small EJ. Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol 2005;23: 1028-43.
5. Gnarra JR, Zhou S, Merrill MJ, et al. Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. Proc Natl Acad Sci U S A 1996;93:10589-94.
6. Gnarra JR, Duan DR, Weng Y, et al. Molecular cloning of the von Nippel-Lindau tumor suppressor gene and its role in renal carcinoma. Biochim Biophys Acta 1996;1242:201-10.
7. Turner KJ, Moore JW, Jones A, et al. Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation. Cancer Res 2002;62:2957-61.
8. Takahashi A, Sasaki H, Kim SJ, et al. Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis. Cancer Res 1994;54:4233-7.
9. Gnarra JR, Tory K, Weng Y, et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 1994;7:85-90.
10. Jacobsen J, Grankvist K, Rasmuson T, Bergh A, Landberg G, Ljungberg B. Expression of vascular endothelial growth factor protein in human renal cell carcinoma. BJU Int 2004;93:297-302.
11. Gabrilovich DI, Ishida T, Nadaf S, Ohm JE, Carbone DP. Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin Cancer Res 1999;5:2963-70.
12. Gerber HP, Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 2005;65:671-80.
13. Rowe DH, Huang J, Kayton ML, et al. Anti-VEGF antibody suppresses primary tumor growth and metastasis in an experimental model of Wilms' tumor. J Pediatr Surg 2000;35:30-2: discussion 2-3.
14. Willett CG, Boucher Y, di Tomaso E, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004;10:145-7.
15. Hurwitz HI, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335-42.
16. Kabbinavar FF, Schulz J, McCleod M, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 2005;23: 3697-705.
17. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307:58-62.
18. Willett C, Chung DC, Sahani DV, et al. Phase I study of neoadjuvant bevacizumab, 5-flourouacil, and radiation therapy followed by surgery for patients with primary rectal cancer. Proc Am Soc Clin Oncol 2004;23:267.
19. Baluk P, Hashizume H, McDonald DM. Cellular abnormalities of blood vessels as targets in cancer. Curr Opin Genet Dev 2005;15:102-11.
20. Mass R, Sarkar S, Holden S, Hurwitz H. Clinical benefit from bevacizumab in responding and non-responding patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 2005;23:249s.
21. Lyons JF, Wilhelm S, Hibner B, Bollag G. Discovery of a novel Raf kinase inhibitor. Endocr Relat Cancer 2001;8:219-25.
22. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-109.
23. Chang YS, Henderson A, Xue D, et al. BAY 43-9006 (sorafenib) inhibits ectopic (s.c.) and orthotopic growth of a murine model of renal adenocarcinoma (Renca) predominantly through inhibition of tumor angiogenesis. Proc Amer Assoc Cancer Res 2005; 46:5831.
24. Nanus DM, Mentle IR, Motzer RJ, Bander NH, Albino AP. Infrequent ras oncogene point mutations in renal cell carcinoma. J Urol 1990;143:175-8.
25. Rochlitz CF, Peter S, Willroth G, et al. Mutations in the ras protooncogenes are rare events in renal cell cancer. Eur J Cancer 1992;28:333-6.
26. Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM. SU11248 inhibits KIT and platelet-derived growth factor receptor β in preclinical models of human small cell lung cancer. Mol Cancer Ther 2003;2:471-8.
27. Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003;9:327-37.
28. O'Farrell AM, Abrams TJ, Yuen HA, et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003;101:3597-605.
29. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003;111:1287-95.
30. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349:427-34.
31. Yang JC. Bevacizumab for patients with metastatic renal cancer: an update. Clin Cancer Res 2004;10: 6367-70S.
32. Escudier B, Szczylik C, Eisen T, et al. Randomized phase III trial of the multi-kinase inhibitor BAY 43-9006 in patients with advanced renal cell carcinoma. Eur J Cancer Suppls 2005;3:226.
33. Ratain MJ, Eisen T, Stadler WM, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:2505-12.
34. Motzer RJ, Dror Michaelson M, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:16-24.
35. Motzer RJ, Rini BI, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006;295:2516-24.
36. Bukowski RM, Kabbinavar F, Figlin RA, et al. Bevacizumab with or without erlotinib in metastatic renal cell carcinoma (RCC) [abstract 4523]. J Clin Oncol 2006;24:222s.
37. Escudier B, Szczylik C, Demkow T, et al. Randomized phase II trial of the multi-kinase inhibitor sorafenib versus interferon (IFN) in treatment-naive patients with metastatic renal cell carcinoma (mRCC) [abstract 4501]. J Clin Oncol 2006;24:217s.
38. Motzer RJ, Hutson TE, Tomczak P, et al. Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa (IFN-a) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC) [abstract LBA3]. J Clin Oncol 2006;24:2s.
39. Yuan F, Chen Y, Dellian M, Safabakhsh N, Ferrara N, Jain RK. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci U S A 1996;93:14765-70.
40. Veronese ML, Mosenkis A, Flaherty KT, et al. Mechanisms of hypertension associated with BAY 43-9006. J Clin Oncol 2006;24:1363-9.
41. Sulzbacher I, Birner P, Traxler M, Marberger M, Haitel A. Expression of platelet-derived growth factor-α α receptor is associated with tumor progression in clear cell renal cell carcinoma. Am J Clin Pathol 2003;120: 107-12.
42. Xu L, Tong R, Cochran DM, Jain RK. Blocking platelet-derived growth factor-D/platelet-derived growth factor receptor β signaling inhibits human renal cell carcinoma progression in an orthotopic mouse model. Cancer Res 2005;65:5711-9.
43. Slaton JW, Perrotte P, Inoue K, Dinney CP, Fidler IJ. Interferon-α-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. Clin Cancer Res 1999;5:2726-34.
44. Nair S, Boczkowski D, Moeller B, Dewhirst M, Vieweg J, Gilboa E. Synergy between tumor immunotherapy and antiangiogenic therapy. Blood 2003;102: 964-71.
45. Strumberg D, Richly H, Hilger RA, et al. Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005; 23:965-72.
46. Ahmad T, Eisen T. Kinase inhibition with BAY 43-9006 in renal cell carcinoma. Clin Cancer Res 2004; 10:6388-92S.
47. Suppiah R, Finke J, Rini BI, et al. T regulatory cells in patients with metastatic renal cell carcinoma decrease during sunitinib treatment: correlations with clinical responses and T helper 1/T helper 2 (Th1/Th2) bias. Proc Am Soc Clin Oncol 2006;24:106s.
48. Rini BI, Halabi S, Taylor J, Small EJ, Schilsky RL. Cancer and Leukemia Group B 90206: a randomized phase III trial of interferon-α or interferon-α plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma. Clin Cancer Res 2004;10:2584-6.
49. Gollob JA, Richmond T, Jones JL, et al. Phase II trial of sorafenib plus interferon-α 2b (IFN-α2b) as first- or second-line therapy in patients with metastatic renal cell cancer. Proc Am Soc Clin Oncol 2006;24:226s.
50. Ryan CW, Goldman BH, Lara PN, Beer TM, Drabkin HA, Crawford ED. Sorafenib plus interferon-α2b (IFN) as first-line therapy for advanced renal cell carcinoma (RCC): SWOG 0412. Proc Am Soc Clin Oncol 2006; 24:223s.
51. Sosman JA, Flaherty K, Atkins MB, et al. A phase I/II trial of sorafenib (S) with bevacizumab (B) in metastatic renal cell cancer (mRCC) patients (Pts) [abstract 3031]. J Clin Oncol 2006;24:128s.
52. Azad NS, Posadas EM, Kwitkowski VE, et al. Increased efficacy and toxicity with combination anti-VEGF therapy using sorafenib and bevacizumab [abstract 3004]. J Clin Oncol 2006;24:121s.
53. Lager DJ, Slagel DD, Palechek PL. The expression of epidermal growth factor receptor and transforming growth factor α in renal cell carcinoma. Mod Pathol 1994;7:544-8.
54. Moch H, Sauter G, Buchholz N, et al. Epidermal growth factor receptor expression is associated with rapid tumor cell proliferation in renal cell carcinoma. Hum Pathol 1997;28:1255-9.
55. Shen BQ, Metz T, Fiebig HH, Meng G, Sliwkowski M, Zioncheck TF. Effect of combination therapy targeting both VEGF and EGF receptor signaling pathways in human renal-cell carcinoma explants. Proc Amer Assoc Cancer Res 2004;45:3007.
56. Hainsworth JD, Sosman JA, Spigel DR, Edwards DL, Baughman C, Greco A. Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J Clin Oncol 2005;23:7889-96.
57. Spigel DR, Hainsworth JD, Sosman JA, et al. Bevacizumab and erlotinib in the treatment of patients with metastatic renal carcinoma (RCC): update of a phase II multicenter trial [abstract 4540]. J Clin Oncol 2005; 23:387s.
58. Hudes G, Carducci M, Tomczak P, et al. A phase 3, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-α (IFN) or the combination of TEMSR + IFN in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma (adv RCC) [abstract LBA4]. J Clin Oncol 2006;24:2s.
59. Rini BI, George DJ, Michaelson MD, et al. Phase II study of sunitinib malate (SU11248) in bevacizumab-refractory metastatic renal cell carcinoma (mRCC) [abstract 4380]. Ann Oncol 2006;17:144s.
60. Tamaskar I, Shaheen P, Wood L, et al. Antitumor effects of sorafenib and sunitinib in patients (pts) with metastatic renal cell carcinoma (mRCC) who had prior therapy with anti-angiogenic agents [abstract 4597]. J Clin Oncol 2006;24:240s.
61. DePrimo SE, Bello CL, Smeraglia J, et al. Soluble protein biomarkers of pharmacodynamic activity of the multitargeted kinase inhibitor SU11248 in patients with metastatic renal cell carcinoma. Proc Amer Assoc Cancer Res 2005;46:464.
62. Rini BI, Jaeger E, Weinberg V, et al. Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status. BJU Int 2006;98:756.
63. Posadas EM, Kwitkowski V, Liel M, et al. Clinical synergism from combinatorial VEGF signal transduction inhibition in patients with advanced solid tumors - early results from a phase I study of sorafenib (BAY 43-9006) and bevacizumab. Eur J Cancer Suppls 2005;3:419.
64. De Mulder PH, Roigas J, Gillessen S, et al. A phase II study of sunitinib administered in continuous daily regimen in patients with cytokine-refractory metastatic renal cell carcinoma. Proc Am Soc Clin Oncol 2006;24:223s.